MD An­der­son es­tab­lish­es new $50M+ biotech fund to choose the next promis­ing can­cer ther­a­pies

Re­searchers at MD An­der­son have a new part­ner to help them get ear­ly-stage pro­grams in­to the clin­ic.

In con­junc­tion with The Fo­cus Fund, MD An­der­son is launch­ing the Can­cer Fo­cus Fund to ad­vance in­ves­ti­ga­tion­al can­cer ther­a­pies from late pre­clin­i­cal de­vel­op­ment through Phase I and Phase Ib/II clin­i­cal tri­als. The fund will start off with more than $50 mil­lion of ini­tial cap­i­tal.

“With­out ap­pro­pri­ate sup­port, we know that some ther­a­pies with great po­ten­tial may be de­layed, may not be de­vel­oped prop­er­ly in the clin­i­cal set­ting or may nev­er make it in­to clin­i­cal stud­ies,” MD An­der­son se­nior VP Fer­ran Prat said in a state­ment. “Through in­vest­ment from the Can­cer Fo­cus Fund and the sup­port of MD An­der­son, we hope to ad­vance worth­while new treat­ments past the tra­di­tion­al hur­dles in the drug de­vel­op­ment process.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER